An operational Schedule M compliant pharmaceutical manufacturing unit producing tablets, oral liquids, capsules and external preparations is available for full sale near Roorkee, Haridwar district, Uttarakhand, India. This GMP plant was commissioned in 2022 and holds valid State manufacturing licences on Form 25 and 28 for allopathic products. The proposed transaction is a complete sale of the company and manufacturing facility with plant, machinery and regulatory approvals, at an asking price of approximately INR 11 crore. The Pharma Plant for Sale in Roorkee is currently operational and suited for both own-brand and third-party formulations, subject to buyer’s strategy and product mix.
Key Highlights
- Schedule M compliant GMP pharmaceutical manufacturing facility commissioned in 2022, with no hazardous, toxic or hormonal products handled at site.
- Dosage forms include tablets, capsules, oral liquids and external preparations (creams, lotions, shampoos etc.), enabling a diversified product portfolio.
- Located at Bhagwanpur, near Roorkee in Haridwar district, Uttarakhand, around 195 km from Delhi NCR and approximately 2.5 hours’ drive.
- Total land area of about 1,556.76 square metres (approx. 16,735 sq ft) with RCC construction and PU panel cleanroom interiors, providing compliant production spaces.
- Two-floor building with around 2,218 sq m (approx. 24,000 sq ft) built-up area, including dedicated manufacturing, packing, QA/QC, utilities, stores and expansion hall on the second floor.
- State Drug Control licences (Form 25 & 28) valid up to December 2027, along with GMP certification under the Drugs & Cosmetics Act Schedule M.
- Installed utilities include purified water system (1000 LPH RO with loop and 2000 L storage), 400 kg/hr diesel boiler, 30 kW compressed air system and 15 TR chiller.
- Effluent treatment plant of 10 KLD capacity with consent valid up to 2028, and RCC internal roads for easy material and vehicle movement.
- Asking price around INR 11 crore for complete company and facility; ideal for Indian pharma group, contract manufacturers or strategic investors looking for a ready Schedule M plant in North India.
Location & Regulatory Approvals
The plant is located at Bhagwanpur, in the Roorkee–Haridwar pharma belt of Uttarakhand, a recognised hub with access to skilled manpower, vendors and logistics. It lies roughly 195 km from Delhi NCR, offering road connectivity that typically allows a travel time of about 2.5 to 3 hours for management, clients and regulators. Adequate open space surrounds the building, and internal roads are RCC constructed, enabling smooth truck movement and safe segregation of manufacturing and utility zones.
The facility operates under State Drug Control administration in Uttarakhand, with manufacturing activities aligned to Schedule M of the Indian Drugs & Cosmetics Act. It holds valid manufacturing licences on Form 25 and Form 28 for tablets, capsules, oral liquids and external preparations, valid up to 8 December 2027. A GMP certificate is in place from the State authority, and products are presently supplied to the Indian domestic market across multiple states.
Infrastructure, Layout & Installed Capacities
The total land parcel measures approximately 1,556.76 square metres (around 16,735 sq ft), with RCC construction and cleanroom interiors using PU puff panels, flushed doors and walkable ceilings in manufacturing areas. The built-up area is about 1,109 sq m per floor, giving a total constructed area of roughly 2,218 sq m (about 24,000 sq ft) over two floors. The ground floor houses production, packing, QA/QC, RM/PM stores, utilities and water system, while the upper level includes a large RCC hall and PM store, providing future expansion headroom.
Manufacturing Areas & Dosage Forms
Ground floor production areas are organised by dosage form for efficient material flow and GMP segregation. Key spaces and indicative sizes include:
- Capsule manufacturing: approx. 400 sq ft.
- Tablet manufacturing: approx. 400 sq ft with tray dryer, blender, compression machine, milling and shifting equipment, and conventional 48-inch coating pan with hot air system.
- External preparation manufacturing: approx. 600 sq ft with semi-automatic contra and rotary mixer (300 kg PLC-operated plant with load cell, bottom homogeniser and variable speed control).
- Oral liquid manufacturing: approx. 600 sq ft with two SS manufacturing tanks (1000 L with stirrer; 500 L with bottom homogeniser and top stirrer) and 1000 L storage tank.
- Tablets and capsules packing sections: strip packing (250 sq ft), blister packing (350 sq ft) and alu-alu packing (350 sq ft) with Vertipack machines (double-track blister, single-track alu-alu, double-track strip machine).
- External preparation filling: tube filling (350 sq ft) with fully automatic PLC linear tube filling machine from RBS Pharma, plus 350 sq ft area for semi-automatic lotion/shampoo filling.
- Liquid filling: approx. 450 sq ft with four-head semi-automatic filling and sealing machine with turntable, sticker labeller (round and flat containers) and conveyor.
The second floor includes a large RCC hall of around 14,000 sq ft plus a PM store of about 2,200 sq ft, offering significant flexibility for new production lines, warehousing or office development as per buyer’s plan.
Warehousing & Laboratories
Raw material and primary/secondary packing material stores on the ground floor cover approximately 2,300 sq ft, designed to support adequate inventory and controlled storage conditions. A dedicated PM store of about 2,200 sq ft on the second floor further strengthens packaging material logistics and allows segregation as per product type.
The QA/QC area of roughly 450 sq ft is provided on the ground floor with laboratory facilities suitable for routine chemical and physical testing; a separate space for microbiology or stability can be configured by the buyer within the existing footprint if required. Clean PU panel construction, walkable ceilings and defined material/people flows help maintain controlled environments in critical areas and support compliance during regulatory inspections.
Utilities & Support Systems
The plant is equipped with critical utilities sized to support current operations with additional buffer for scale-up.
Key utility highlights:
- Purified water system based on RO with mixed-bed polishing, rated at 1000 LPH, connected to a loop line and 2000 L storage tank for reliable supply to manufacturing areas.
- 400 kg/hr diesel-fired steam boiler (Neomax make) supporting manufacturing, cleaning and sterilisation requirements.
- Compressed air system of 30 kW, fully automatic with air drying, for pneumatic operations and equipment utilities.
- 15 TR water chiller capable of providing chilled water down to approximately 5°C, useful for HVAC and process cooling.
- 500 kVA transformer with servo voltage stabiliser to ensure stable power to equipment and HVAC loads.
- Effluent Treatment Plant (ETP) of 10 KLD capacity located away from the main building, with environmental consent valid up to 2028.
The plant has dedicated areas for AHU utilities (about 1,665 sq ft) and water system (about 260 sq ft), supporting installation of zoned HVAC and distribution systems consistent with GMP manufacturing. Ancillary facilities such as internal RCC roads, parking pockets and perimeter walls provide safe access, material movement and security, while admin and support spaces can be further customised by the incoming buyer.
Business & Financial Snapshot
The company currently operates as a closely held, professionally managed GMP pharmaceutical manufacturer supplying formulations to the domestic Indian market under a mix of own-label and contract manufacturing arrangements, depending on client needs. Current annual turnover and EBITDA levels can be shared with serious buyers upon execution of a confidentiality agreement, but the unit has been structured to operate at a reasonable scale with scope for ramp-up under a stronger marketing or third-party manufacturing base.
Therapeutic and product categories include general oral solid and liquid formulations along with external preparations suitable for multiple therapy segments such as pain management, gastro, anti-infectives, vitamins, dermatological and personal-care type products, subject to buyer’s portfolio. Client types typically include Indian pharmaceutical companies seeking loan-licence or third-party manufacturing partners, regional marketing companies and distributors; no toxic, hazardous or hormonal products are manufactured, which simplifies compliance and environmental management.
Strategic Advantages & Expansion Potential
Acquiring this tablets, capsules, oral liquids and external preparations pharmaceutical manufacturing unit near Roorkee offers a faster route to market compared to greenfield development in North India. The plant is already commissioned, fitted-out with PU panel cleanrooms, and holds valid licences up to late 2027, allowing a buyer to commence or scale commercial production in a relatively short timeframe following transfer and re-endorsement of licences.
Location-wise, the facility benefits from the established pharma ecosystem of Haridwar–Roorkee with access to experienced workforce, formulation development expertise and packaging vendors, along with road connectivity to Delhi NCR and other major markets. Policy incentives linked to Uttarakhand’s industrial zones and common pharma cluster advantages (logistics, ancillary manufacturers, warehousing) can further improve cost competitiveness for the buyer, subject to current state schemes.
Expansion potential is significant: the large second-floor RCC hall (around 14,000 sq ft) and open spaces allow installation of additional manufacturing lines such as higher-capacity tablet equipment, dedicated nutraceutical or cosmetic sections, or even specialised regulated-market blocks, depending on buyer’s strategic priorities. Furthermore, the existing base of installed utilities, ETP, and cleanroom envelope reduces incremental capex for upgrades such as higher classification areas, additional AHUs or automation systems for data integrity.
Deal Terms & Ideal Buyer
The proposed transaction is a full sale of the operating company along with its manufacturing facility, land, building, plant & machinery, utility systems, valid licences and associated documentation. Detailed scopes around transfer of product dossiers, brand names, existing contracts and key employees can be discussed during negotiations and structured to ensure smooth transition.
The seller is open to a standard upfront consideration structure consistent with similar mid-size pharma manufacturing transactions in India, with the asking price indicated at around INR 11 crore for the complete asset; alternative structures such as staged payments or minority participation can be considered with credible buyers where strategic value is strong. The ideal buyer profile includes Indian pharmaceutical groups, established contract development and manufacturing organisations (CDMOs), mid-market pharma marketers seeking backward integration, or financial investors/PE funds looking for a ready Schedule M platform in North India.
Strict confidentiality is expected, with detailed financials, customer information and technical documentation shared only after execution of an NDA and initial profile screening. Site visits for technical and EHS due diligence can be scheduled on mutually convenient dates, usually after preliminary discussions on valuation and structure.
Contact & Next Steps
Serious and qualified buyers are invited to express interest in this GMP-compliant tablets, oral liquids, capsules and external preparation pharma plant for sale in Roorkee, Uttarakhand. Basic profile details (company name, business model, regulatory focus and intended use of the asset) are requested with the initial enquiry to facilitate a focused discussion and timely sharing of further information.
Contact for this opportunity:
- Name: Darshan Singh
- Role: Promoter representative
- Email: contact@laafon.com
- Phone / WhatsApp: 9812446733
Interested parties may route their enquiries through the listing platform, indicating “Pharma Unit For Sale in Roorkee, Haridwar – REF_ID” in the subject line to enable efficient handling and tracking.
Frequently Asked Questions
Is the pharma plant currently operational?
Yes, the plant is currently operational with manufacturing and packing of tablets, capsules, oral liquids and external preparations being carried out under Schedule M compliant conditions as per State licences. Production can be scaled up or rebalanced depending on the buyer’s product portfolio and regulatory strategy after takeover.
What regulatory approvals and licences does the facility hold?
The unit holds State manufacturing licences on Form 25 and Form 28 (licence numbers 11/UA/2022 and 8/UA/SC/P-2022) for allopathic formulations, valid up to 8 December 2027, along with GMP certification issued by the Uttarakhand Drug Control Authority. All activities follow Schedule M requirements under the Drugs & Cosmetics Act and are monitored by the Directorate of Medical Health and Family Welfare, Dehradun.
Which markets are currently served from this plant?
The facility currently caters to the Indian domestic market across multiple states through own-label and contract manufacturing arrangements, without export registrations at present. A buyer can leverage the existing infrastructure to pursue additional state registrations or export markets after undertaking necessary regulatory upgrades and filings.
Are brand names, product registrations and existing staff included in the sale?
The transaction primarily covers land, building, plant & machinery, licences and associated documentation; inclusion of any brand names, product permissions, dossiers and key staff will be discussed with serious buyers and can be structured based on mutual agreement. The seller is open to facilitating a smooth transition of core technical and operational personnel where this supports continuity.
What information is shared before and after signing an NDA?
At the enquiry stage, investors typically receive a high-level overview of the facility, approvals, key equipment and asking price range similar to this listing. Detailed financial statements, customer lists, product permission lists, validation and qualification documents, and other sensitive data are made available only after execution of a mutual NDA and confirmation of genuine buying intent.
How are site visits and technical due diligence handled?
Site visits are usually organised after preliminary discussions and NDA execution, allowing buyer technical teams to inspect manufacturing areas, utilities, documentation systems and ETP. Subsequent detailed due diligence involving regulatory, EHS, quality systems and financial reviews can be scheduled in multiple rounds as needed, with data-room access provided through a structured process.
Is there flexibility between full sale and JV or minority stake?
The current preference is a full sale of the company and plant to a strategic or financial buyer; however, the promoters may consider a joint venture or majority stake sale if the partner brings strong market access, export capability or growth capital. Any alternative structures will be evaluated on a case-by-case basis, with commercial terms aligned to market norms.
What is the typical timeline for closing the deal?
Subject to buyer readiness, regulatory processes and due diligence, an indicative closing timeline of around 3 to 6 months from signing of definitive agreements is realistic for this type of transaction. The promoters are motivated to complete the deal in an orderly manner, with reasonable flexibility to accommodate buyer’s internal approval processes.
